Preview Mode Links will not work in preview mode

Sep 9, 2019

Breast Cancer Update, Issue 2, 2019 — Part 1: Our interview with Dr Hurvitz highlights the following topics as well as cases from her practice:

  • Optimal duration of adjuvant trastuzumab; analysis of the results from the Phase III PERSEPHONE and PHARE studies (00:00)
  • Perspective on the role of trastuzumab biosimilar agents in the management of HER2-positive breast cancer (04:43)
  • Benefits and risks of anthracycline-containing and anthracycline-free neoadjuvant regimens for patients with HER2-positive disease (08:03)
  • Comparison of paclitaxel/trastuzumab/pertuzumab to TCHP in the neoadjuvant setting (11:17)
  • Activity of pertuzumab in combination with T-DM1 in the (neo)adjuvant and metastatic settings (13:21)
  • Case: A woman in her mid-40s with ER-positive, HER2-positive breast cancer attains a good response to neoadjuvant T-DM1/pertuzumab on the KRISTINE study (16:15)
  • KRISTINE: A Phase III study of neoadjuvant TCHP versus T-DM1/pertuzumab for HER2-positive breast cancer (19:05)
  • Primary analysis of SOPHIA: A Phase III study of the novel anti-HER2 antibody margetuximab and chemotherapy versus trastuzumab and chemotherapy for pretreated HER2-positive mBC (22:58)
  • Case: A woman in her late 40s with HER2-positive mBC receives trastuzumab deruxtecan on a clinical trial after experiencing disease progression on tucatinib (27:17)
  • Ongoing Phase II HER2CLIMB study investigating tucatinib with capecitabine and trastuzumab for advanced HER2-positive breast cancer (31:06)
  • Emerging data with trastuzumab deruxtecan for patients with advanced HER2-positive breast cancer who received prior treatment with T-DM1 (33:32)
  • Potential clinical role of trastuzumab deruxtecan (37:10)
  • Preemptive measures to mitigate nausea and the risk of pneumonitis associated with trastuzumab deruxtecan (38:45)
  • Case: A woman in her early 40s with HER2-positive mBC experiences a prolonged remission with trastuzumab and lapatinib in combination with chemotherapy (41:22)
  • Predictors of benefit with HER2-targeted therapy; risk of recurrence for patients with HER2-positive breast cancer (47:05)
  • Role of CDK4/6 inhibitors for patients with ER-positive, HER2-positive mBC; activity of PI3K inhibitors in patients with PIK3CA mutations (50:30)
  • Neratinib and capecitabine versus lapatinib and capecitabine for HER2-positive mBC previously treated with HER2-directed therapy: Findings from the Phase III NALA trial (52:40)

CME information and select publications